ConnecticutWomen Quality Measures Compared to Achievable Benchmarks

The NHQDR quality measures specific to Women are compared to achievable benchmarks, which are derived from the top-performing States. Better performance of a State can mean higher or lower values of a measure, depending on the desired outcome. For example, low values are desirable for measures such as infant mortality, whereas high values are desirable for measures such as preventative screening. The categories of achievement have been standardized across the measure definitions so that:

 
Far away from benchmark - a State's value for a measure has not achieved 50% of the benchmark.
 
Close to benchmark - a State's value for a measure is between 50% and 90% of a benchmark (i.e., worse than the benchmark but has achieved at least half of the benchmark but not as much as 90% of a benchmark).
 
Achieved benchmark or better - a State's value for a measure is no worse than 90% of the benchmark value, the measure has achieved the benchmark. This category also includes the case in which the measure’s value is equal to or better than the benchmark.
Measures That Achieved Benchmark or Better
Measure Population Estimate Benchmark Distance to Benchmark
Adults ages 18-64 at high risk (e.g., COPD) who received an influenza vaccination in the last flu season Female 48.9 47.8 Achieved: 2% better
Adults who received a blood cholesterol measurement in the last 5 years Female 83.8 82.3 Achieved: 2% better
Women under age 70 treated for breast cancer with breast-conserving surgery who received radiation therapy to the breast within 1 year of diagnosis Total 96.6 97.0 0.4%
Breast cancer deaths per 100,000 female population per year Total 18.3 17.8 2.9%
Women with clinical Stage I-IIb breast cancer who received axillary node dissection or sentinel lymph node biopsy (SLNB) at the time of surgery (lumpectomy or mastectomy) Total 92.2 96.8 4.8%
Adults age 65 and over who ever received pneumococcal vaccination Female 74.7 78.7 5.1%
Adults age 65 and over who received an influenza vaccination in the last flu season Female 65.2 70.3 7.3%
Adults age 40 and over with diagnosed diabetes who received at least two hemoglobin A1c measurements in the calendar year Female 72.0 79.5 9.4%
Measures That Are Close to Benchmark
Measure Population Estimate Benchmark Distance to Benchmark
Cervical cancer diagnosed at advanced stage (all invasive tumors) per 100,000 women age 20 and over Total 8.4 7.6 11.1%
Adults age 40 and over with diagnosed diabetes who received a flu vaccination in the calendar year Female 58.1 65.8 11.8%
Adults age 40 and over with diagnosed diabetes who received a dilated eye examination in the calendar year Female 66.1 75.2 12.1%
Adults age 40 and over with diagnosed diabetes who had their feet checked for sores or irritation in the calendar year Female 70.8 84.0 15.7%
Breast cancer diagnosed at advanced stage (regional, distant stage, or local stage with tumor greater than 2 cm) per 100,000 women age 40 and over Total 85.9 72.8 18.0%
Adults ages 18-64 at high risk (e.g., COPD) who ever received pneumococcal vaccination Female 26.7 44.8 40.4%
Measures That Are Far From Benchmark
Measure Population Estimate Benchmark Distance to Benchmark
Hospital inpatient stays involving opioid-related diagnoses per 100,000 population Female 377.7 102.9 267.2%
Emergency department visits involving opioid-related diagnoses per 100,000 population Female 288.9 65.2 342.8%
Measures With No Available Benchmark Information or Supplemental Measures
Measure Population Estimate Benchmark Distance to Benchmark
Radiation therapy was recommended or administered following any mastectomy within 1 year of diagnosis of breast cancer for women with 4 positive regional lymph nodes Total 91.1
Tamoxifen or third generation aromatase inhibitor was recommended or administered within 1 year of diagnosis for women with AJCC T1cN0M0 or stage IB to stage III hormone receptor-positive breast cancer Total 90.4
Combination chemotherapy was recommended or administered within 4 months of diagnosis for women under 70 with AJCC T1cN0MO or Stage IB-III hormone receptor negative breast cancer Total 93.4
People who needed to see a doctor but could not because of cost in the past 12 months Female 11.7